[Treatment of primary disease for synchronous metastatic prostate cancer].
Irradiation de la maladie primitive des cancers de la prostate avec métastases synchrones.
Clinical trials
Metastatic
Metastatic cancer
Primary tumour
Prostate
Radiotherapy
SBRT
Stereotactic radiotherapy
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
05
2020
revised:
10
06
2020
accepted:
17
06
2020
pubmed:
29
8
2020
medline:
9
10
2020
entrez:
29
8
2020
Statut:
ppublish
Résumé
The management of early metastatic prostate cancer is based on systemic treatment by androgen deprivation therapy with or without chemotherapy or next-generation anti-androgen therapies. Local treatment of the prostate was initially used only to alleviate local symptoms. However, local radiotherapy of the prostate has been the subject of retrospective and prospective studies in patients with better prognostic factors, particularly in oligometastatic status. The results of these studies support that prostate radiotherapy can prolong the survival of patients with a low metastatic burden. This article states the biological bases, the main published and future published studies aimed to embed this strategy to optimize therapeutic management.
Identifiants
pubmed: 32855028
pii: S1278-3218(20)30181-5
doi: 10.1016/j.canrad.2020.06.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
547-553Informations de copyright
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.